Oslo, Norway, 8 December 2016

Reference is made to the announcement made earlier today regarding sale of shares by primary insider Jostein Dahle, and the announcement made on 6 December 2016 regarding the Company's launch of a private placement of new shares.
As stated in the launch announcement of the private placement, the Company, its board members, executive management and major shareholder have all agreed with the Joint Bookrunners to a lock-up for a period of 180 days from the closing date of the private placement, subject to customary and de minimis exceptions. Jostein Dahle's share sale was made under the de minimis exception and was conducted to finance personal obligations.



About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at